NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.55% | 24.07% | 3.25% | -36.75% | -123.75% |
| Total Depreciation and Amortization | 1.76% | -3.13% | 1.84% | 1.13% | 1.34% |
| Total Amortization of Deferred Charges | 12.06% | 5.47% | 5.47% | 5.47% | 5.47% |
| Total Other Non-Cash Items | 45.82% | -18.51% | -23.80% | -17.64% | -8.03% |
| Change in Net Operating Assets | -112.30% | -19.01% | -85.61% | -91.83% | 151.38% |
| Cash from Operations | 64.04% | 40.02% | -223.68% | -596.86% | -338.20% |
| Capital Expenditure | -58.18% | -52.54% | -48.31% | -46.69% | -26.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -146.10% | 234.97% | 113.44% | 2,226.91% | 278.11% |
| Cash from Investing | -176.16% | 53.95% | 94.06% | 964.57% | 231.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -129,030.00% | -75,858.82% | -53,704.17% | 89.29% | 64.29% |
| Issuance of Common Stock | -60.08% | -68.04% | -67.55% | -38.58% | 1.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 472.08% | 417.96% | 345.92% | -38.50% | 1.91% |
| Foreign Exchange rate Adjustments | -232.82% | 79.07% | -139.47% | 209.68% | 235.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.34% | 137.35% | 105.21% | 5,526.42% | 235.14% |